Emcure Pharmaceuticals announced its financial results for the first quarter of FY27, reporting a revenue of ₹25,804 million, a 22.8% increase year-over-year. Profit After Tax (PAT) rose by 36.2% to ₹2,925 million. The company highlighted strong performance driven by both domestic and international business segments, with international revenue growing by 34.2%.
Emcure Pharmaceuticals Reports Strong Q1 FY27 Financials
Emcure Pharmaceuticals has released its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27), demonstrating robust growth across key financial metrics. The company recorded a total revenue from operations of ₹25,804 million, marking a significant year-over-year increase of 22.8%. This performance reflects the company’s sustained expansion and market strength.
Profitability and Margins Improve
The company’s profitability saw a substantial boost, with Profit After Tax (PAT) reaching ₹2,925 million, up by 36.2% compared to the same period in the previous year. The PAT margin improved to 11.3% from 10.2% in Q1 FY26, indicating enhanced operational efficiencies and margin expansion. EBITDA also grew by 25.8% to ₹5,080 million, with the EBITDA margin increasing to 19.7%.
Segment Performance Highlights
The international business segment was a key contributor to the overall growth, with revenues increasing by 34.2% year-over-year. This growth was driven by strong performance across Europe, Rest of the World (RoW), and Canada. The domestic business also showed resilience, with a growth of 10.2%, contributing 42% to the total revenue mix, while international operations accounted for the remaining 58%.
Other Financial Data Points
In terms of other financial indicators, R&D expenditure stood at ₹904 million for Q1 FY27. Capital Expenditure (CAPEX) was ₹1,168 million. The Net Debt to TTM EBITDA ratio was reported at 0.6x as of June 30, 2026.
The presentation on the unaudited financial results for the quarter ended June 30, 2026, is also available on the company’s website, www.emcure.com.
Source: BSE
